Related Experiment Videos
The basic science of periprosthetic osteolysis.
M J Archibeck1, J J Jacobs, K A Roebuck
1Department of Orthopaedic Surgery, Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, USA.
Instructional Course Lectures
|May 25, 2001
Summary
Wear in total joint replacements causes bone loss (osteolysis), limiting implant longevity. Understanding cellular and chemical factors is key to developing new treatments for periprosthetic bone loss.
Area of Science:
- Biomaterials Science
- Orthopedic Surgery
- Immunology
- Cell Biology
Background:
- Wear debris and its consequences remain primary limitations for total joint replacement longevity.
- Aseptic loosening, recognized decades ago, is linked to periprosthetic osteolysis.
- Significant advancements have been made in understanding the basic science of osteolysis.
Purpose of the Study:
- To review the current understanding of the cellular and molecular mechanisms underlying periprosthetic osteolysis.
- To highlight the key cellular participants and chemical mediators involved in bone resorption around joint implants.
- To discuss the potential for pharmacologic interventions based on recent research.
Main Methods:
- Review of existing literature on tissue explant, animal, and cell culture studies.
- Analysis of cellular interactions and chemical mediators implicated in osteolysis.
- Examination of research on signaling pathways contributing to periprosthetic bone loss.
Main Results:
- Identified key cellular players: macrophages, osteoblasts, fibroblasts, and osteoclasts.
- Highlighted critical chemical mediators: prostaglandin E2 (PGE2), tumor necrosis factor-alpha (TNF-alpha), interleukin-1 (IL-1), and interleukin-6 (IL-6).
- Signaling pathway research is advancing the understanding of bone loss mechanisms.
Conclusions:
- Osteolysis in total joint replacements involves complex interactions between various cells and inflammatory mediators.
- Pharmacologic agents targeting these pathways show promise in preclinical studies.
- Further well-controlled human trials are necessary to validate potential treatments for osteolysis.